Moberg Pharma AB (FRA:MB8) Shares Outstanding (EOP): 47.00 Mil (As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.81
GF Value €1.07
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Shares Outstanding (EOP)?

Moberg Pharma AB FRA:MB8 +2.28% 59 Shares Outstanding (EOP) is 47.00 Mil as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Moberg Pharma AB's shares outstanding for the quarter that ended in Mar. 2026 was 47.00 Mil.

Moberg Pharma AB's quarterly shares outstanding stayed the same from Dec. 2025 (47.00 Mil) to Mar. 2026 (47.00 Mil).

Moberg Pharma AB's annual shares outstanding increased from Dec. 2023 (27.96 Mil) to Dec. 2024 (46.69 Mil). It means Moberg Pharma AB issued new shares from Dec. 2023 to Dec. 2024 .


Moberg Pharma AB  (FRA:MB8) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Moberg Pharma AB Shares Outstanding (EOP) Related Terms


Moberg Pharma AB Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Shares Outstanding (EOP) Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.11 6.84 14.74 27.96 46.69

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.69 47.00 47.00 47.00 47.00

FRA:MB8 vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Shares Outstanding (EOP) falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 47.00 Mil mean?
Moberg Pharma AB (FRA:MB8) has a Shares Outstanding (EOP) of 47.00 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Shares Outstanding (EOP) too high?
Moberg Pharma AB's current Shares Outstanding (EOP) is 47.00 Mil. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Shares Outstanding (EOP) compare to ZTS and UTHR?
Moberg Pharma AB's Shares Outstanding (EOP) of 47.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Shares Outstanding (EOP) is 47.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Shares Outstanding (EOP) of 47.00 Mil. The stock's GF Value™ is €1.07, compared to a current price of €0.81 — trading 24.6% below its estimated fair value. The current Shares Outstanding (EOP) is 47.00 Mil. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Shares Outstanding (EOP) is 47.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.81 is trading 24.6% below its estimated GF Value™ of €1.07.

Key valuation signals for FRA:MB8:

  • Shares Outstanding (EOP): 47.00 Mil
  • GF Value™: €1.07 vs. price of €0.81 (24.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.81
Price
€1.07
GF Value